Skip to main content

Cardio/Pulmonary

Implementing Smoking Cessation Programs

Apr 07, 2021

Rheumatologists are keen to the effects of smoking (increased arthritis risk, worse outcomes, blunted DMARD responses, added cardiopulmonary risks), but often do not have the resources or plan to encourage or implement smoking cessation from the rheumatology clinic. A new study details the

Read Article

Rituximab in Systemic Sclerosis?

Apr 05, 2021

No drug is FDA approved to manage the skin or joint complaints of systemic sclerosis (SSc); a recent metanalysis suggests that rituximab may improve skin score and disease activity indices (DAS, mRSS) while stabilizing organ involvement in SSc patients.

Read Article

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Apr 02, 2021

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Read Article

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

Mar 31, 2021

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.



Data derived from the retrospective

Read Article
Metanalysis of 32 studies shows most forms of arthritis assoc w/ incr risk of CVA (ischemic stroke: RR=1.53 or hemorrhagic stroke: RR=1.45), esp for RA (RR=1.38), AS (RR=1.49), PsA (RR=1.33), gout (RR=1.4) --risk higher with age <45 years (RR=1.46) https://t.co/YDiebrqtbi

Dr. John Cush @RheumNow( View Tweet )

Mar 31, 2021

RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)

Mar 26, 2021

Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.




  1. Analysis of CPRD registry and 15,670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY and half that

Read Article
News Feature: Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease https://t.co/2P0tdxvZD2 https://t.co/7gfE1CPSEx
Dr. John Cush @RheumNow( View Tweet )
Mar 22, 2021
Leading the Rheumatoid Arthritis pod with discussions on pneumonia and RA and interstitial lung disease in RA. #RNL2021 https://t.co/psxMTHsOva
Dr. John Cush @RheumNow( View Tweet )
Mar 20, 2021
Top 4 arthritis types that significantly increase the risk of CVA: 1) RA (RR=1.38), 2) ankylosing spondylitis (RR=1.49), 3) psoriatic arthritis (RR=1.33) & gout (RR=1.4). With these, the risk was higher in younger (<45 yrs) (RR = 1.46), not older (>65) https://t.co/Snb6OrtZJH

Dr. John Cush @RheumNow( View Tweet )

Mar 19, 2021

Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease

Mar 19, 2021

There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.

Read Article
Other recommendations from Dr Calabrese @CCalabreseDO today @AWIRGROUP Summit. #WomeninRheum education everyone. https://t.co/YahmODVEw2
WOMEN IN RHEUM @AWIRGROUP( View Tweet )
Mar 14, 2021

Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Mar 08, 2021

Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults SSc-ILD.

Read Article
#RA associated interstifial lung dz has incidence of 1-5 per 1,000 PYs and prevalence as high as 67%; risk factors; age, male sex, Dz duration, CCP Abs; w/ age as best predictor of mortality. There is no clear drug interventions that helps RA-ILD https://t.co/zJvWqt0w6L

Dr. John Cush @RheumNow( View Tweet )

Mar 08, 2021
News Feature: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease https://t.co/6A4muejeH9 https://t.co/xQbIoEEscv
Dr. John Cush @RheumNow( View Tweet )
Mar 07, 2021

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Mar 04, 2021

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article
Today the FDA approved tocilizumab (Actemra) for use in Systemic Sclerosis-Associated Interstitial Lung Disease for "Slowing the rate of decline in pulmonary function in adult patients with SSc-ILD" Rec dose is 162 mg SC q week (IV dose not approved) https://t.co/HXTRPiYEfZ

Dr. John Cush @RheumNow( View Tweet )

Mar 04, 2021
While RA incurrs a 2 fold risk of CHF; the use of HCQ does not add to a CHF risk. Mayo nested case-control study, compared RA w/ CHF vs nonCHF RA pts, showing HCQ use, nor duration of use, failed to increase CHF (OR: 0.96).https://t.co/Tx9jr07C7i

Dr. John Cush @RheumNow( View Tweet )

Mar 04, 2021

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Feb 26, 2021

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

Read Article
We are excited to announce that Jeff Sparks ( @jeffsparks) will be leading a discussion on ILD in RA at RheumNow Live this March. Register to attend today. https://t.co/uwxOVh142F https://t.co/bnittqkhKQ
Dr. John Cush @RheumNow( View Tweet )
Feb 23, 2021
Lung Preservation w/ Tocilizumab in Early Systemic Sclerosis Arthritis & Rheumatology has published the results of a subanalysis from TCZ clinical trials showing that Il-6 inhibition is related with preservation of lung function patients with early SSc. https://t.co/2BwWQWEkri https://t.co/pjVc8YTDwU
Dr. John Cush @RheumNow( View Tweet )
Feb 23, 2021
CTD associated pulmonary HTN has improved sincd 2010. Metanalysis of 11 RCTs (4,329 pts) & 19 registries (9,739 pts); 5 RCTs find PAH Rx assoc w/ 36% lower mortality/morbidity. Registry data shows better PAH survival since 2010 (73% vs 65% @3yrs) https://t.co/0BkO70AQfi

Dr. John Cush @RheumNow( View Tweet )

Feb 22, 2021
Analysis of incident #RA in UK Clinical Practice registry shows recent prednisone >=7.5mg/d is assoc w/ hypertension in RA. In 17760 RA pts, 42% were Rx steroids; recent GC yielded a 17% increase in HTN (HR 1.17); only >7.5mg/D implicated https://t.co/qUKs2oZZUV https://t.co/pWmD4nKs6U
Dr. John Cush @RheumNow( View Tweet )
Feb 22, 2021

Lung Preservation with Tocilizumab in Early Systemic Sclerosis

Feb 21, 2021

Arthritis & Rheumatology has published the results of a subanalysis from tocilizumab (TCZ) clinical trials showing that Il-6 inhibition was associated with preservation of lung function patients with early systemic sclerosis (SSc).

Read Article

Alveolar Hemorrhage and Mortality in Lupus

Feb 17, 2021

Metanalysis of patients with diffuse alveolar hemorrhage (DAH), show this to be a rare and life-threatening complication of systemic lupus erythematosus (SLE), that is more apt to affect older, severe lupus patients with active infection.

Read Article
Dr. Shenoi Suspect autoinflammatory Dz: patterned fevers MSK and skin involvement Serositis Other - aphthous ulcers, CNS (stroke, basal ganglia calcification,) ILD, LN, lipodystrophy) ethnicity (FMF or Mediterranean) Family Hx -- Testing options! #RWCS2021 @RheumNow @RWCSmtg https://t.co/DZk4hsxbk4
Dr. Rachel Tate @uptoTate( View Tweet )
Feb 13, 2021
×